Helixgate

Helixgate

Uncategorized

Summit slips on ivonescimab’s apparent interim miss in sign of investor frustration

Published

on

Summit Therapeutics’ stock price {$SMMT} tumbled nearly 20% after the closing bell Thursday afternoon, following an apparent statistical miss in part of a Phase 3 trial for its cancer drug ivonescimab.

In patients with a …

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Summit’s ‘self-inflicted’ stumble; Esperion’s take-private deal

Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.

Read More

Published

on

Summit’s decision to conduct an interim analysis of a closely watched trial backfired. Elsewhere, Axsome got a much-needed label expansion and an FDA committee sided against an AstraZeneca breast cancer medicine.

Read More

Continue Reading

Uncategorized

Samsung Biologics workers begin five-day strike over wage disputes 

Samsung Biologics workers begin five-day strike over wage disputes 

Published

on

After holding a rally in April, Samsung Biologics union workers on Friday started a five-day strike over wage negotiations.

Around 95% of the company’s union members voted on the strike, with the …​ ​Read More

Continue Reading

Uncategorized

Acelyrin founder Shao-Lee Lin emerges at Cue, as it becomes latest to license from China

Published

on

Cue Biopharma announced a reboot Thursday afternoon, bringing in notable biotech executive Shao-Lee Lin as well as a new allergy asset developed in Taiwan and mainland China.

The Boston-based biotech has focused on developing T …

Continue Reading
Advertisement

Trending